Actinium Pharmaceuticals (ATNM) Net Cash Flow (2010 - 2026)
Actinium Pharmaceuticals (ATNM) posted quarterly Net Cash Flow of -$5.9 million for Q1 2026, up 22.45% year-over-year from -$4.8 million in Q1 2025, and down 11.02% quarter-over-quarter from -$5.3 million in Q4 2025.
Actinium Pharmaceuticals (ATNM) Net Cash Flow (2010 - 2026) Analysis & Trends
Actinium Pharmaceuticals (ATNM) has reported Net Cash Flow for 16 consecutive years, with -$5.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow rose 22.45% year-over-year to -$5.9 million; the TTM figure through Mar 2026 stood at -$23.1 million (down 23.37% YoY), while the FY2025 annual figure was -$24.9 million, down 561.91% from the prior year.
- Net Cash Flow declined to -$5.9 million in Q1 2026 per ATNM's latest filing, from -$5.3 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $44.3 million in Q2 2022 and bottomed at -$14.4 million in Q1 2023.
- Historically, Net Cash Flow has averaged -$2.1 million across 5 years, with a median of -$5.8 million in 2024.
- On a YoY basis, Net Cash Flow climbed as much as 358.75% in 2022 and fell as far as 3610.83% in 2022.
- Actinium Pharmaceuticals' Net Cash Flow stood at -$2.9 million in 2022, then sank by 117.1% to -$6.3 million in 2023, then increased by 8.64% to -$5.8 million in 2024, then advanced by 8.03% to -$5.3 million in 2025, then fell by 11.02% to -$5.9 million in 2026.
- Business Quant data shows ATNM's Net Cash Flow at -$5.9 million in Q1 2026, -$5.3 million in Q4 2025, and -$6.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.92 Bn | 131.07 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.91 Bn | 77.91 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.87 Bn | 59.68 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.18 Bn | 53.04 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.96 Bn | 36.87 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.23 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 27.79 Bn | 9.40 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.37 Bn | 26.53 Bn | - | 225.59 Mn |
| 10 | Actinium Pharmaceuticals | 34.85 Mn | 34.85 Mn | - | -5.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.66 Mn |
| Jun 30, 2026 | -5.66 Mn |
| Mar 31, 2026 | -5.88 Mn |
| Mar 31, 2026 | -5.88 Mn |
| Dec 31, 2025 | -5.29 Mn |
| Dec 31, 2025 | -5.29 Mn |
| Sep 30, 2025 | -6.53 Mn |
| Sep 30, 2025 | -6.53 Mn |
| Jun 30, 2025 | -5.40 Mn |
| Jun 30, 2025 | -5.40 Mn |
| Mar 31, 2025 | -7.58 Mn |
| Mar 31, 2025 | -7.58 Mn |
| Dec 31, 2024 | -5.75 Mn |
| Dec 31, 2024 | -5.75 Mn |
| Sep 30, 2024 | -7.37 Mn |
| Sep 30, 2024 | -7.37 Mn |
| Jun 30, 2024 | 1.98 Mn |
| Jun 30, 2024 | 1.98 Mn |
| Mar 31, 2024 | 7.38 Mn |
| Mar 31, 2024 | 7.38 Mn |